Xenopus laevis oocytes infected with multi-drug-resistant bacteria: implications for electrical recordings
Student AuthorsKaren Mruk
UMass Chan AffiliationsDepartment of Animal Medicine
Department of Biochemistry and Molecular Pharmacology
Document TypeJournal Article
KeywordsXenopus laevis; Oocytes; Drug Resistance, Multiple, Bacterial; Laboratory Techniques and Procedures
Medicine and Health Sciences
MetadataShow full item record
AbstractThe Xenopus laevis oocyte has been the workhorse for the investigation of ion transport proteins. These large cells have spawned a multitude of novel techniques that are unfathomable in mammalian cells, yet the fickleness of the oocyte has driven many researchers to use other membrane protein expression systems. Here, we show that some colonies of Xenopus laevis are infected with three multi-drug-resistant bacteria: Pseudomonas fluorescens, Pseudomonas putida, and Stenotrophomonas maltophilia. Oocytes extracted from infected frogs quickly (3-4 d) develop multiple black foci on the animal pole, similar to microinjection scars, which render the extracted eggs useless for electrical recordings. Although multi-drug resistant, the bacteria were susceptible to amikacin and ciprofloxacin in growth assays. Supplementing the oocyte storage media with these two antibiotics prevented the appearance of the black foci and afforded oocytes suitable for whole-cell recordings. Given that P. fluorescens associated with X. laevis has become rapidly drug resistant, it is imperative that researchers store the extracted oocytes in the antibiotic cocktail and not treat the animals harboring the multi-drug-resistant bacteria.
SourceO'Connell, D., et al., Xenopus laevis oocytes infected with multi-drug-resistant bacteria: implications for electrical recordings. J Gen Physiol. 2011 Aug;138(2):271-7. Link to article on publisher's website
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/33210
Related ResourcesLink to article in PubMed
RightsThis article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).